FDA expands use of controversial J&J antidepressant

The FDA approved a Johnson & Johnson drug for a new class of people with depression disorders Aug. 3 despite concerns about its potential to be abused because it contains a once-popular party drug.

Previously, the drug, Spravato, was only approved for people with treatment-resistant depression. Now people with major depressive disorder with acute suicidal ideation or behavior will be allowed to take the drug.